Does applying technology throughout the medication use process improve patient safety with antineoplastics?

Joseph Bubalo, Bruce A. Warden, Joshua J. Wiegel, Tess Nishida, Evelyn Handel, Leanne M. Svoboda, Lam Nguyen, P. Neil Edillo

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Purpose: Medical errors, in particular medication errors, continue to be a troublesome factor in the delivery of safe and effective patient care. Antineoplastic agents represent a group of medications highly susceptible to medication errors due to their complex regimens and narrow therapeutic indices. As the majority of these medication errors are frequently associated with breakdowns in poorly defined systems, developing technologies and evolving workflows seem to be a logical approach to provide added safeguards against medication errors. Summary: This article will review both the pros and cons of today's technologies and their ability to simplify the medication use process, reduce medication errors, improve documentation, improve healthcare costs and increase provider efficiency as relates to the use of antineoplastic therapy throughout the medication use process. Several technologies, mainly computerized provider order entry (CPOE), barcode medication administration (BCMA), smart pumps, electronic medication administration record (eMAR), and telepharmacy, have been well described and proven to reduce medication errors, improve adherence to quality metrics, and/or improve healthcare costs in a broad scope of patients. The utilization of these technologies during antineoplastic therapy is weak at best and lacking for most. Specific to the antineoplastic medication use system, the only technology with data to adequately support a claim of reduced medication errors is CPOE. In addition to the benefits these technologies can provide, it is also important to recognize their potential to induce new types of errors and inefficiencies which can negatively impact patient care. Conclusion: The utilization of technology reduces but does not eliminate the potential for error. The evidence base to support technology in preventing medication errors is limited in general but even more deficient in the realm of antineoplastic therapy. Though CPOE has the best evidence to support its use in the antineoplastic population, benefit from many other technologies may have to be inferred based on data from other patient populations. As health systems begin to widely adopt and implement new technologies it is important to critically assess their effectiveness in improving patient safety.

Original languageEnglish (US)
Pages (from-to)445-460
Number of pages16
JournalJournal of Oncology Pharmacy Practice
Issue number6
StatePublished - Dec 20 2014
Externally publishedYes


  • Technology
  • chemotherapy errors
  • patient safety

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Does applying technology throughout the medication use process improve patient safety with antineoplastics?'. Together they form a unique fingerprint.

Cite this